Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUSCAR: Luseogliflozin effects on arterial properties and blood pressure in Japanese T2DM
jRCTs031180434Completed
- Sponsor
- Taisho Pharmaceutical
- Start
- May 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of luseogliflozin in type 2 diabetes mellitus (T2DM), sponsored by Taisho Pharmaceutical. Primary endpoint: Change in cardio-ankle vascular index (CAVI). Started May 2019; status: completed.
02
Drugs
luseogliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on jRCTs031180434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031180434.